ଲେକାନେମାବ

ଲେକାନେମାବ
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	Beta amyloid
Clinical data
Trade names	Leqembi
Synonyms	BAN2401, lecanemab-irmb
AHFS/Drugs.com	monograph
data	US DailyMed: Lecanemab;
Routes of; administration	Intravenous
Legal status
Legal status	US: ℞-only ;
Chemical and physical data
Formula	C6544H10088N1744O2032S46
Molar mass	୧,୪୭,୧୮୧.୬୨ g·mol−1

ଲେକାନେମାବ (ଇଂରାଜୀ ଭାଷାରେ Lecanemab) , ବିକ୍ରୟ ନାମ ଲେକ୍ୱେମ୍ବି, ହେଉଛି ଆଲଜିମର ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୨] ସାମାନ୍ୟ ରୋଗ ହୋଇଥିଲେ ଏହା ବ୍ୟବହୃତ ହୁଏ ଓ ଏହା ଫଳରେ ଆମିଲଏଡ ପ୍ଲେକ୍ ହ୍ରାସ ହେବାର ଦେଖାଯାଏ ।^[୨] ଏହି ଚିକିତ୍ସାର ଫଳ ଅର୍ଥପୂର୍ଣ୍ଣ ଦେଖାଯାଏ ନାହିଁ ।^[୩] ^[୪] ଏହା ଏକ ଶିରାରେ ଧୀରେ ଧୀରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡ ବିନ୍ଧା, ଅନ୍ତର୍ନିଧାନ ବା ଇନଫ୍ୟୁଜନ୍ ପ୍ରତିକ୍ରିୟା ଏବଂ ମସ୍ତିଷ୍କ ଫୁଲା ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆମିଲଏଡ ସମ୍ବନ୍ଧୀୟ ଇମେଜିଙ୍ଗ୍ ଅସ୍ୱାଭାବିକତା (ARIA) ହୋଇପାରେ ।^[୨] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଆମିଲଏଡ ବିଟା ସହିତ ସଂଲଗ୍ନ ହୋଇ କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୨]

୨୦୨୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଲେକାନେମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ୨୦୨୩ରେ ଏହାର ନିର୍ମାତା ୟୁରୋପରେ ଅନୁମୋଦନ ପାଇଁ ଏକ ଅନୁରୋଧ କରିଥିଲେ ।^[୫] ଏହା କାନାଡ଼ାରେ ଅନୁମୋଦିତ ନୁହେଁ | ^[୪] ୭୫ କିଲୋଗ୍ରାମ ବ୍ୟକ୍ତିଙ୍କ ପାଇଁ ଏହା ବାର୍ଷିକ ପ୍ରାୟ ୨୬,୫୦୦ ଆମେରିକୀୟ ଡଲାର ଖର୍ଚ୍ଚ ହୁଏ ।^[୬]

ଆଧାର

↑ "Leqembi (lecanemab-irmb) injection, for intravenous use Initial U.S. Approval: 2023" (PDF). Eisai Inc. January 2023. Archived (PDF) from the original on 7 January 2023. Retrieved 7 January 2023.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ "DailyMed - LEQEMBI- lecanemab injection, solution". dailymed.nlm.nih.gov. Archived from the original on 15 January 2023. Retrieved 12 January 2023.
↑ Mahase, Elisabeth (2022-12-01). "Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain". BMJ (in ଇଂରାଜୀ). 379: o2912. doi:10.1136/bmj.o2912. ISSN 1756-1833. PMID 36455963. Archived from the original on 2023-03-17. Retrieved 2023-06-17.
↑ ^୪.୦ ^୪.୧ Kolber, Michael. "#369 Remind me, do medications that target brain amyloid improve my dementia? – CFPCLearn". Archived from the original on 9 July 2024. Retrieved 9 July 2024.
↑ "Eisai submits MAA for lecanemab in Europe". European Pharmaceutical Review (in ଇଂରାଜୀ). Archived from the original on 11 January 2023. Retrieved 12 January 2023.
↑ "Eisai's Approach To U.S. Pricing For Leqembi (Lecanemab), a Treatment For Early Alzheimer's Disease, Sets Forth Our Concept Of "Societal Value Of Medicine" In Relation To "Price Of Medicine"" (Press release). Eisai Inc. 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023.

[Leqembi_FDA_label-1] "Leqembi (lecanemab-irmb) injection, for intravenous use Initial U.S. Approval: 2023" (PDF). Eisai Inc. January 2023. Archived (PDF) from the original on 7 January 2023. Retrieved 7 January 2023.

[PI2023-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ "DailyMed - LEQEMBI- lecanemab injection, solution". dailymed.nlm.nih.gov. Archived from the original on 15 January 2023. Retrieved 12 January 2023.

[3] Mahase, Elisabeth (2022-12-01). "Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain". BMJ (in ଇଂରାଜୀ). 379: o2912. doi:10.1136/bmj.o2912. ISSN 1756-1833. PMID 36455963. Archived from the original on 2023-03-17. Retrieved 2023-06-17.

[CF2024-4] ୪.୦ ^୪.୧ Kolber, Michael. "#369 Remind me, do medications that target brain amyloid improve my dementia? – CFPCLearn". Archived from the original on 9 July 2024. Retrieved 9 July 2024.

[5] "Eisai submits MAA for lecanemab in Europe". European Pharmaceutical Review (in ଇଂରାଜୀ). Archived from the original on 11 January 2023. Retrieved 12 January 2023.

[PRN2023-6] "Eisai's Approach To U.S. Pricing For Leqembi (Lecanemab), a Treatment For Early Alzheimer's Disease, Sets Forth Our Concept Of "Societal Value Of Medicine" In Relation To "Price Of Medicine"" (Press release). Eisai Inc. 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]